ReviewCurrent neurology and neuroscience reports2026
Advances in Multimodality Monitoring in Traumatic Brain Injury.
Review in Current neurology and neuroscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewMultimodal monitoring (MMM) has the potential to transform the management of secondary brain injury following traumatic brain injury (TBI) to enable more personalized care. Despite its promise, the optimal combination of monitoring modalities and the interpretation of complex data streams remain insufficiently mature for MMM to be considered standard of care. This review evaluates the current state of MMM technologies, their clinical applications, and their emerging role in improving TBI management and guiding the path toward broader clinical adoption. This review focuses on real-time physiological data streams that can provide management guidance in a time frame commensurate with the onset of sudden events such as seizures, brain hypoxic events, and excursions of cerebral hypertension. Thus, we do not cover more static modalities such as imaging and biomarkers. RECENT
findingsRecent studies highlight the potential of MMM to reduce variability in TBI outcomes associated with secondary insults. Integration of physiological variables-such as intracranial pressure, brain tissue oxygenation, arterial blood pressure, and electroencephalography-combined with artificial intelligence (AI) and advanced analytics, may enable earlier detection and prediction of adverse events. However, key challenges remain, including the need for larger harmonized datasets, standardized acquisition and interpretation methods, and prospective validation of multimodal-guided interventions. MMM is emerging as a cornerstone technology to enhance patient phenotyping in TBI, enabling more individualized and timely therapeutic interventions. Continued advances in data integration, analytics, and standardization will be essential to translate MMM from a promising research tool into a validated component of precision neurocritical care.
Indexed as
Identifiers
42734883What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.